RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL …
WEB18 hours ago · Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE ... - Markets …
WEB1 day ago · Recordati will host a conference call today, 4 th October, at 13:00 CEST (12:00 p.m. GMT) to discuss the agreement to acquire Enjaymo®.The dial-in numbers for the conference call service are ...
Recordati to Buy Global Rights to Sanofi's Enjaymo for $825 ...
WEB17 hours ago · Global News Select Recordati to Buy Global Rights to Sanofi's Enjaymo for $825 Million Provided by ... Enjaymo's revenue amounted to around 100 million euros ($110.3 million) for the 12 months to ...
Recordati buys rights to rare immune disorder drug from ...
WEB18 hours ago · Follow. Oct 4 (Reuters) - Italian pharma group Recordati (RECI.MI) said on Friday it would buy from Sanofi (SASY.PA) the global rights to a drug used to treat cold agglutinin disease (CAD), a rare ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL …
WEB18 hours ago · Enjaymo® generated approximately € 100 million in revenue over the last 12 months as of August 2024 and is expected to generate revenue in excess of € 150 million in FY 2025, with peak sales ...
Recordati buys rights to rare immune disorder drug from ...
WEB1 day ago · October 4, 2024 at 2:10 AM. (Reuters) - Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold agglutinin disease (CAD), a rare ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL …
WEB18 hours ago · /EIN News/ -- Enjaymo® (sutimlimab) is a humanized monoclonal antibody indicated for the treatment of hemolysis in adults with CAD. In 2022, it was granted approval by the U.S. Food and Drug ...
Company Announcements - Financial Times
WEB18 hours ago · Enjaymo® is a humanized monoclonal antibody that is designed to selectively target and inhibit C1s in the classical complement pathway, which is part of the innate immune system. By blocking C1s, Enjaymo® inhibits the activation of the complement cascade in the immune system and inhibits C1-activated hemolysis in CAD to prevent the abnormal ...
Press Room - Sanofi US News
WEBJan 25, 2023 · The US Food and Drug Administration (FDA) has approved the expanded indication for Enjaymo ® (sutimlimab-jome), the first and only treatment of hemolysis in adults with cold agglutinin disease (CAD), to include patients with or …
FDA approves treatment for adults with rare type of anemia
WEBFeb 4, 2022 · FDA has approved Enjaymo (sutimlimab-jome) infusion to decrease the need for red blood cell transfusion due to hemolysis (red blood cell destruction) in adults with cold agglutinin disease...
- Some results have been removed